
Kainomyx: Biotech firm specializing in malaria and parasitic disease therapeutics.
Kainomyx is a biotechnology company founded with the mission to develop innovative therapeutics for malaria and other parasitic diseases. The company's vision is to combat and ultimately eradicate these life-threatening conditions through cutting-edge scientific research and development. Kainomyx focuses on creating effective treatments that address the urgent global health challenge posed by malaria, aiming to improve patient outcomes and reduce mortality rates.
Notable figures affiliated with Kainomyx include leading scientists and researchers in the field of parasitology and infectious diseases. The company has attracted significant investment from prominent venture capital firms dedicated to advancing healthcare solutions. Key achievements include the development of promising drug candidates that have shown efficacy in preclinical trials. Kainomyx's impact is marked by its potential to transform malaria treatment protocols and contribute to global health initiatives aimed at eradicating parasitic diseases.

Kathera Bioscience
katherabio.com

Kymera Therapeutics
kymeratx.com

Selva Therapeutics
selvarx.com

Petri Bio
petribio.com

Nano Cures
nanocures.com

MarvelBiome
marvelbiome.com

Capacity Bio
capacitybio.com

Myrobalan Therapeutics
myrotx.com

PAQ Therapeutics
paqtx.com

Kovina Therapeutics
kovina.com

Paratus Sciences

Intellimedix
intellimedix.com

KeifeRx
keiferx.com

Zymeron
zymeron.com

Microbiotix
microbiotix.com

Qlaris Bio
qlaris.bio

OptiKira

FF EAI Robotics Ecosystem

AimMax Therapeutics
aimmaxrx.com

MIMOSA Therapeutics
Kainomyx's most recent funding round was for $2M (USD) in May 2020.
As of May 1, 2020, Kainomyx has disclosed funding of $2M (USD).